Arthritis Genetics Analysis Aids Drug Discovery
News Jan 14, 2014
Rheumatoid arthritis is a chronic inflammatory disorder that can cause pain, swelling, stiffness, and loss of function in joints throughout the body. It’s an autoimmune disease, in which the immune system mistakenly attacks the body’s own tissue, such as the membranes that line the joints. It can also affect other parts of the body besides the joints.
The causes of rheumatoid arthritis aren’t completely known. Environmental factors—such as cigarette smoking, diet, and stress—may play a role in triggering the disease. Genetic factors are also thought to play a role. Several genes involved in the immune system have been associated with a tendency to develop rheumatoid arthritis.
An international team of researchers, led by Drs. Robert Plenge, formerly of Harvard Medical School, and Yukinori Okada from RIKEN Center for Integrative Medical Sciences in Japan, conducted a genome-wide association study (GWAS). This type of analysis involves scanning genetic regions in search of tiny variations that appear more often in people who have a particular condition than in those who don't.
Scientists from 70 institutions worldwide were involved in the study, which was funded in part by NIH's National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and National Institute of General Medical Sciences (NIGMS). Results appeared online in Nature on December 25, 2013.
The team analyzed 10 million gene variants from more than 100,000 people of European and Asian descent, including more than 29,000 people with rheumatoid arthritis and 73,000 controls. The researchers identified 42 new areas in the genome that are associated with rheumatoid arthritis, bringing the total number of known areas to 101. The findings suggest that the genetic risk of rheumatoid arthritis may be shared among Asians and Europeans.
Using bioinformatics methods, the scientists identified 98 candidate genes in these areas that might potentially contribute to the onset of rheumatoid arthritis. Further analysis showed a significant overlap among some of the gene regions and genes associated with other conditions, including human primary immunodeficiency and blood cancers.
The researchers analyzed drug databases and found that many of the genes associated with rheumatoid arthritis risk were the targets of drugs approved to treat people with the disease. They further found that risk genes overlapped with drugs approved for other diseases, suggesting these drugs might be repurposed for the treatment of rheumatoid arthritis.
“By leveraging human genetic data, we were able to shed light on genes and pathways that contribute to the onset of rheumatoid arthritis. In the future, this approach could be applied to a variety of other complex diseases to discover new pathways and biological insights for drug discovery,” Plenge says.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.